Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-11

Study Completion Date

2019-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, crossover study with cluster randomization and a planned accrual of 300 patients with diagnosed breast fibroadenoma (One fibroadenoma treated per patient). This is a trial based prospective cost consequence study. Costs will be estimated from the viewpoint of the healthcare system and from the patient's perspective

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma

NCT01422629

Breast Fibroadenoma

COMPLETED NA

Feasibility Study Assessing the Treatment of Fibroadenomata With a Circumferential Sonication Treatment With HIFU

NCT02139683

Breast Fibroadenoma

COMPLETED NA

Efficacy of MR-HIFU Ablation of Breast Cancer

NCT02407613

Breast Cancer

WITHDRAWN NA

Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy

NCT01827969

Breast Tumor

WITHDRAWN NA

Radiofrequency of Breast Cancers in Non Surgical Patients

NCT00210223

Breast Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fibroadenomas are well-circumscribed benign tumors, easily distinguishable from adjacent normal breast tissue on ultrasound images.

The goal of this protocol is to compare HIFU and surgery in terms of cost, safety, and clinical effectiveness for the treatment of nonmalignant breast tumors.

Fibroadenomas appear to be an ideal target for evaluation of ultrasound guided HIFU treatment. However, not all the FA are suitable for surgical treatment and in many cases surveillance associated or not with hormonal medication may be sufficient for limiting the symptoms at the degree compatible with a good quality of life for the patients. In addition, from the fraction of the patients for which ablation is a genuine medical need due to the severity of the pathology (size, symptoms, disturbed daily activity with possible psychological impact), only a part of them are suitable for undergoing the HIFU treatment.

Therefore, all the patients to be included in this study have an initial indication of surgical resection of the adenoma. Unlike the patients presenting FA and suitable for medication and surveillance, the cases for which surgery is an indication are symptomatic (significant pain, discomfort, anxiety) and/or are presenting a growth observed during their surveillance with ultrasound examination. In addition, all the eligible patients will have to comply with the technical limitations of the HIFU method in terms of lump size, subcutaneous depth, presence of calcifications and other contraindications like presence of breast implants or under areolar location. Knowing that after the age of 45 years the lumps are in many institutions reserved exclusively for surgery in order to eliminate all suspicion of malignancy, the upper age limit is fixed at 45. Further limitations as established by the American Society of Breast Surgeons for potential candidates of percutaneous excision will be added as inclusion criteria for all patients (the lesion must be sonographically visible, the diagnosis of FA must be confirmed histologically, lesions should be less than 4cm in largest diameter).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Fibroadenoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This is a multicentrer, crossover study with cluster randomization. In the cross over design, 1/2 of the centers are randomized to start the trial with HIFU and the other 1/2 with surgery. In the cluster randomized crossover (CXRO), all participating cluster receive both the intervention and control in a sequence determined at random

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Surgery

Group Type ACTIVE_COMPARATOR

Surgery

Intervention Type PROCEDURE

Traditional open excisional surgery

HIFU (Echopulse)

Group Type ACTIVE_COMPARATOR

HIFU (Echopulse)

Intervention Type DEVICE

High intensity focused ultrasound (HIFU) non invasive intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surgery

Traditional open excisional surgery

Intervention Type PROCEDURE

HIFU (Echopulse)

High intensity focused ultrasound (HIFU) non invasive intervention

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patients 18 to 45 years old with at least one diagnosed breast fibroadenoma
* Diagnosis of fibroadenoma must be based on:

* clinical examination
* ultrasound image alone for patients Under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. the BI-RADS score of this mammogram must be less than 3. In all cases where an uncertainly exists, the patient will not be included.
* histological confirmation after core needle biopsy by two independant readers (biopsy must be performed at least two weeks before therapy unless a micro biopsy has been already done less than 3 months before inclusion visit and histopathology slices are available)
* the requirements for the distance from the skin and the following régions of the fibroadenoma are:

* depth anterior edge \< 19.4mm
* nodule thickness \> 7.3 mm
* depth of posterior edge \> 12.5 mm
* depth to rib cage \> 10mm
* patient's fibroadenoma size is greater to equal to 0.3 cc (measured by ultrasound on the day of the procedure)
* Lesions should be less than 20 mL
* The lesion must be sonographically visible
* Lesions presented during previous surveillance a minimum 20% increase volume AND/OR
* Patient are presenting a pain level \>= 3 as meaured on the VAS during the last 30 days AND/OR
* Patient are presenting a anxiety level \>= 3 as meaured on the VAS during the last 30 days before selection visit
* Fibroadenoma is palpable
* Patient candidate for sugery
* Patient has signed a written informed consent
* Patient with a social security coverage

Exclusion Criteria

* Patient is pregnant or lactating
* Patient with history of laser or radiotherapy in the targeted breast
* Core biopsy diagnosis suggestive of cytosarcoma phyllodes tumor or other malignancy
* Patient with breast implant in the targeted breast
* Patient with predominantly liquid nodule
* Macro-calcifications in pre-focal HIFU path
* Nipple and or areola in pre-focal HIFU path
* Patient's fibroadenoma not clearly visible on the ultrasound images (in B-mode) at the inclusion visit
* Scars or moles before the focal point of the HIFU
* Patient participating in another clinical trial involving an investigational drug, or device

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No